Business Standard
Thursday, Feb 16, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Commodities
 

Bafna Pharma to enter US
Shahani Fatima / Chennai Nov 04, 2009, 00:08 IST

Eyes 3-fold growth in revenues next financial year

Chennai-based pharmaceuticals company Bafna Pharmaceuticals Limited expects a three-fold growth in revenues to Rs 125 crore in the next financial year from the present Rs 40 crore on the back of its entry into the US market.

BSE | NSE
Price  
bafna pharmaceuticals
 Click here for Cloud Computing
 
 
 
Related Stories
News Now
“We are in the process of filing ANDAs (abbreviated new drug applications) in the US for anti-retro viral drugs for AIDS,” Bafna Mahaveer Chand, chairman and managing director of the company, told Business Standard. The ANDA is likely to get approved in 18 months and thereafter the company plans to diversify by offering more lifestyle drugs.

This apart, it is looking at exports too boost its revenues. Currently, the revenue from domestic and exports is equally balanced.

The chairman said they would penetrate deeper into the European market and seek approval from the Medicine and Health Regulatory Agency for selling steroids there. It has already acquired six clients in Europe for contract manufacturing and has applied for seven variations.

“Looking ahead contract manufacturing will boost our business. Still, it is necessary for a pharma company to also have brands,” he said.

The company is, therefore, eyeing a shift from generic formulations to branding . “We will introduce our products in Sri Lanka by next year and then take them to other Asian markets where we have a presence before bringing them to India, he said.

At present, it exports non-betalactum products to European markets whereas it is into generic formulations in Asian and African markets.

Meanwhile, the company is planning to ramp up its export-oriented manufacturing facility near Chennai with an investment of Rs 37 crore. Around 25 crore will be invested in expanding the capacity of the 700-million tablets per annum facility by next year and Rs 12 crore in setting up an R&D facility for contract manufacturers by December. “We are looking at a 70:30 ratio between debts and internal accruals,” Bafna said on the funding pattern.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- S&P reaches 7-month high before hitting wall
- World Bank President Zoellick to step down on June 30
- Oil cos cut jet fuel prices by Rs 350/kl
- Telcos operating profit to rise 5% in 2 yrs: Crisil
- PESB recommends SS Narsing Rao for CIL's top slot
  Read Business news in 
- Now property search gets more exciting than ever before!
- High Growth Business Opportunities in Africa - Register to explore
- Save over Rs.3000 with IndianOil Citibank Card
- We live for our family. have you secured them?
- India's No. 1 Property Site. Click here to know more..
- Diseases earlier, Saving Costs, Extending Lives. Know More..
- Get 5% cashback on telephone bills with Citi
- Enjoy the journey as much as the destination. click to know more..
- Exim Bank Conclave on India - Africa Project Partnership. Know more..
- Medium-sized businesses are the engines of a smarter planet.
- Be part of it The World's Largest Aircraft.
- Creating Wealth made simple the SIP way. Know more..
- Only Developer to give a guarantee on time space & rate.
- Office 365 for professionals and small businesses.
- Buy Your Property with Our Triple Guarantee in India.
- Improve Patient Care & Experience. Click here to know more
- Win a Business Class Ticket to Europe..Know more..
-  Introduce a New Automotive Luxury Car.. know more
- Health is Wealth..... Insurance + Savings... Know More...
Sorry, comments to this story are closed
Latest Messages
SmartInvestor+ E-zine
  Pay Rs.747/- for 3 years and
  get a branded watch FREE

  Subscribe Now
Most Popular
Read
E-Mailed
Commented
   
- Kanika Datta: The importance of being SRK
- Nestle: Food for thought
- Leela parts ways with Kempinski
- Tailor-made but not good enough
- Tata Motors soars to record level as JLR propels profit
 
 More  
BUSINESS STANDARD INDIA 2012
  Now available at Special price
  Rs.395/- Only
  Buy Now
  Now available on the Kindle Store...
  BS Specials  
    Full coverage of elections in Uttar Pradesh, Punjab, Uttarakhand, Manipur and Goa
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us